Bayesian Capital Management, LP Supernus Pharmaceuticals, Inc. Transaction History

Bayesian Capital Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$27.11 - $35.17 $176,269 - $228,675	6,502 New	6,502 $221,000
Q2 2019 Aug 13, 2019	SELL	$29.96 - $38.87 $410,991 - $533,218	-13,718 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$32.77 - $41.99 $224,179 - $287,253	6,841 Added 99.48%	13,718 $481,000
Q4 2018 Feb 13, 2019	SELL	$30.84 - $49.51 $9,252 - $14,853	-300 Reduced 4.18%	6,877 $228,000
Q3 2018 Nov 14, 2018	BUY	$42.7 - $56.55 $20,069 - $26,578	470 Added 7.01%	7,177 $361,000
Q2 2018 Aug 14, 2018	BUY	$44.1 - $59.85 $295,778 - $401,413	6,707 New	6,707 $401,000

283

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.06B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.